Key result
A carbon ion radiotherapy schedule of 3.0 GyRBE × 17 met critical gastrointestinal dose constraints in 100% of cases, whereas higher dose schedules of 4.6 GyRBE × 12 and 4.0 GyRBE × 14 met them in only 33% and 49% of cases, respectively.
Why the study?
To identify a safe carbon ion radiotherapy regimen for patients with locally advanced pancreatic cancer.
Does a 3.0 GyRBE x 17 CIRT schedule improve the ability to meet gastrointestinal dose constraints compared to higher dose schedules in patients with locally advanced pancreatic cancer?
Observational (n=13)
No
Does a 3.0 GyRBE x 17 CIRT schedule improve the ability to meet gastrointestinal dose constraints compared to higher dose schedules in patients with locally advanced pancreatic cancer?
A more conservative CIRT schedule of 3.0 GyRBE × 17 allows for meeting critical gastrointestinal dose constraints in all patients with LAPC, unlike higher dose schedules.
Answers are grounded in this paper and cite their sources.
Supports 3.0 GyRBE × 17 schedule to meet GI constraints in all LAPC cases; hypothesis-generating for clinical outcomes.
OBJECTIVE: To identify a safe carbon ion radiotherapy (CIRT) regimen for patients with locally advanced pancreatic cancer (LAPC). METHODS: We generated treatment plans for 13 consecutive, unselected patients who were treated for LAPC with CIRT at our center using three dose and fractionation schedules: 4.6 GyRBE × 12, 4.0 GyRBE × 14, and 3.0 GyRBE × 17. We tested the ability to meet published dose constraints for the duodenum, stomach, and small bowel as a function of dose schedule and distance between the tumor and organs at risk. RESULTS: Using 4.6 GyRBE × 12 and 4.0 GyRBE × 14, critical (high-dose) constraints could only reliably be achieved when target volumes were not immediately adjacent to organs at risk. Critical constraints could be met in all cases using 3.0 GyRBE × 17. Low-dose constraints could not uniformly be achieved using any dose schedule. CONCLUSION: While selected patients with LAPC may be treated safely with a CIRT regimen of 4.6 GyRBE × 12, our dosimetric analyses indicate that a more conservative schedule of 3.0 GyRBE × 17 may be required to safely treat a broader population of LAPC patients, including those with large tumors and tumors that approach gastrointestinal organs at risk. The result of this work was used to guide an ongoing clinical trial.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2020) conducted an observational in Locally advanced pancreatic cancer (n=13). Carbon ion radiotherapy (CIRT) fractionation schedules vs. Internal comparison of schedules was evaluated on Rate of achieving critical dose constraints for gastrointestinal organs. A carbon ion radiotherapy schedule of 3.0 GyRBE × 17 met critical gastrointestinal dose constraints in 100% of cases, whereas higher dose schedules of 4.6 GyRBE × 12 and 4.0 GyRBE × 14 met them in only 33% and 49% of cases, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: